Phytopharm shares advance on strategic review update

Development stage pharmaceuticals group Phytopharm has unveiled an update on its on-going strategic review which was initiated following the announcement of headline results from its Phase II clinical trial of Cogane in Parkinson's disease.

Development stage pharmaceuticals group Phytopharm has unveiled an update on its on-going strategic review which was initiated following the announcement of headline results from its Phase II clinical trial of Cogane in Parkinson's disease.

On February 18th, Phytopharm announced that analysis of headline results from its Phase II clinical trial of Cogane in Parkinson's disease indicated that the drug had not demonstrated clinically meaningful efficacy.

In its most recent update, the company said that a full analysis of the complete dataset had now been completed confirming the initial view that no efficacy was demonstrated in the primary or secondary endpoints measured in the study.

"As a result of these findings, no further research and development expenditure will be committed and a staff reduction and cost saving programme has been initiated," the group said.

The group added that it had also initiated a review of the strategic options available to the company, which included the review of a number of merger and acquisition opportunities.

Exploratory discussions had been held with a number of parties, the group added.

Phytopharm's share price was up 3.33% to 1.55p at 10:29 on Tuesday.

MF

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Oil producers are back at their Covid-19 lows – is it time to buy?
Oil

Oil producers are back at their Covid-19 lows – is it time to buy?

With demand for oil hammered by Covid-19 and talk of “peak oil demand”, there are lots of good reasons to be bearish on oil producers. So, asks John S…
22 Sep 2020
Why you should stuff your end-of-pandemic portfolio with Chinese stocks
China stockmarkets

Why you should stuff your end-of-pandemic portfolio with Chinese stocks

For an end-of-pandemic portfolio, you need assets that can cope with today’s volatility. And that, says Merryn Somerset Webb, means Chinese stocks.
14 Sep 2020
IAG's share price is ready for take-off - here's how to play it
Trading

IAG's share price is ready for take-off - here's how to play it

The owner of British Airways has had a turbulent year, but is now worth a punt. Matthew Partridge explains the best way to play it.
8 Sep 2020